ArticleFrontiers in medicine2026
Dickkopf 2 serves as a novel therapeutic target and prognostic biomarker in acute myeloid leukemia targeted by evodiamine.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Acute myeloid leukemia (AML) has seen a significant increase in cases recently, often leading to a poor outlook. Dysregulated cell death is a characteristic of AML that aids in both the formation and advancement of the disease. Dickkopf 2 (DKK2) is known to promote tumorigenesis and metastasis through multiple mechanisms, facilitating cancer development and progression. The specific function of DKK2 in AML is not yet completely understood. Materials and methods: The potential of DKK2 as a prognostic marker in AML was assessed using data from the Gene Expression Omnibus (GEO; accession number GSE26294) and The Cancer Genome Atlas (TCGA). Cell growth, proliferation, apoptosis, and migration were assessed following the upregulation or downregulation of DKK2 in AML cells using CCK-8, EdU staining, AO/EB staining, and transwell assays. Furthermore, molecular docking and dynamics simulations were performed to predict the interaction and binding affinity between DKK2 and evodiamine. Rescue experiments were further conducted to elucidate the functional relationship between DKK2 and evodiamine. Results: In AML, DKK2 expression was notably increased and linked to poor overall survival. Reducing DKK2 levels hindered AML cell growth, proliferation, and migration, while promoting apoptosis. Conversely, overexpression of DKK2 promoted the malignant phenotype of AML cells. Additionally, evodiamine was identified as a potential small-molecule compound that may functionally regulate DKK2 in AML evodiamine showed a strong binding affinity to DKK2, with a binding energy measured at -5.51 kcal/mol. Importantly, the overexpression of DKK2 negated the anti-cancer effects of evodiamine in AML cells. Conclusion: The DKK2/evodiamine axis represents a novel prognostic biomarker and a promising therapeutic target for AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.